An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1

Trial Identifier: D1346R00002
Sponsor: AstraZeneca
NCTID:: NCT03259633

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States of America, LA New Orleans, LA, United States of America, 12345